If you have been reading about Lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Justicia pectoralis Brugmansia sp. (Toé) Opuntia sp. Epiphyllum sp. Cyperus sp. Nicotiana rustica (Mapacho, variety of tobacco) Ilex guayusa, a relative of yerba mate Lygodium venustum, (Tchai del monte) Phrygilanthus eugenioides and Clusia sp (both called Miya) Lomariopsis japurensis (Shoka) Common admixtures with their associated ceremonial values and spirits:
The alkali metals are among the most electropositive elements on the periodic table and thus tend to bond ionically to the most electronegative elements on the periodic table, the halogens (fluorine, chlorine, bromine, iodine, and astatine), forming salts known as the alkali metal halides. The reaction is very vigorous and can sometimes result in explosions. All twenty stable alkali metal halides are known; the unstable ones are not known, with the exception of sodium astatide, because of the great instability and rarity of astatine and francium. The most well-known of the twenty is certainly sodium chloride, otherwise known as common salt. All of the stable alkali metal halides have the formula MX where M is an alkali metal and X is a halogen. They are all white ionic crystalline solids that have high melting points. All the alkali metal halides are soluble in water except for lithium fluoride (LiF), which is insoluble in water due to its very high lattice enthalpy. The high lattice enthalpy of lithium fluoride is due to the small sizes of the Li+ and F− ions, causing the electrostatic interactions between them to be strong: a similar effect occurs for magnesium fluoride, consistent with the diagonal relationship between lithium and magnesium. The alkali metals also react similarly with hydrogen to form ionic alkali metal hydrides, where the hydride anion acts as a pseudohalide: these are often used as reducing agents, producing hydrides, complex metal hydrides, or hydrogen gas. Other pseudohalides are also known, notably the cyanides.
The traditional French preparation involves placing a sugar cube on top of a specially designed slotted spoon and placing the spoon on a glass filled with a measure of absinthe. Iced water is poured or dripped over the sugar cube to mix the water into the absinthe. The final preparation contains 1 part absinthe and 3–5 parts water. As water dilutes the spirit, those components with poor water solubility (mainly those from anise, fennel, and star anise) come out of solution and cloud the drink. The resulting milky opalescence is called the louche (/luʃ/, French: 'opaque' or 'shady'). The release of these dissolved essences coincides with a perfuming of herbal aromas and flavours that "blossom" or "bloom", and brings out subtleties that are otherwise muted within the neat spirit. This reflects what is perhaps the oldest and purest method of preparation, and is often referred to as the French method. The Bohemian method is a recent invention that involves fire, and was not performed during absinthe's peak of popularity in the Belle Époque. Like the French method, a sugar cube is placed on a slotted spoon over a glass containing one shot of absinthe. The sugar is soaked in alcohol (usually more absinthe), and then set ablaze. The flaming sugar cube is then dropped into the glass, thus igniting the absinthe. Finally, a shot glass of water is added to douse the flames. This method tends to produce a stronger drink than the French method. A variant of the Bohemian method involves allowing the fire to extinguish on its own.
=== In development === Several new drugs and treatments are under development for snakebite. For instance, the metal chelator dimercaprol has recently been shown to potently antagonize the activity of Zn2+-dependent snake venom metalloproteinases in vitro. New monoclonal antibodies, polymer gels and a small molecule inhibitor called Varespladib are in development. A core outcome set (minimal list of consensus outcomes that should be used in future intervention research) for snakebite in South Asia is being developed. In an article published in Nature in October 2025, a group led by researchers from the Technical University of Denmark has presented the possibility of a broad-spectrum antivenom that can work against the bites of many different snakes. They have developed an experimental polyvalent recombinant anti-venom that the authors claim to be capable of neutralising seven toxin families or subfamilies. A study conducted by Jacob Glanville used two antibodies taken from the memory B cells of blood from a "hyperimmune" donor, who had been deliberately bitten by many species of snake, to develop an antivenom "cocktail". Elapidae were the focus of the study, of which nineteen are classified as being the deadliest on Earth by the World Health Organization. Tested on mice, the antivenom cocktail prevented death from thirteen of the nineteen species, with partial protection observed from the other six.
In December 2013, NSF launched a lawsuit against MusclePharm and declared that MusclePharm is not authorized to use any NSF certification marks, to claim that any of its products are certified by NSF, or to claim that they have been manufactured in an NSF GMP certified or registered facility. The Tawnsaura Group sued MusclePharm for patent infringement. 2011 Environmental Research Center (ERC) filed a notice of intent to start litigation against over 200 nutrition and supplement companies, including MusclePharm, alleging violations of California Proposition 65. I'm a lawsuit, ThermoLife claimed that MusclePharm infringed ThermoLife's patent on amino acid compounds including creatine nitrate. 2006 MusclePharm was first incorporated.
Sources: en.wikipedia.org
== Cause == CREST syndrome involves the production of autoimmune anti-nuclear (ANA) and anti-centromere antibodies (ACA), though their cause is not currently understood. There is no known infectious cause.
=== Pharmacokinetics === Stanozolol has high oral bioavailability, due to the presence of its C17α alkyl group and the resistance to gastrointestinal and liver metabolism that it results in. The medication has very low affinity for human serum sex hormone-binding globulin (SHBG), about 5% of that of testosterone and 1% of that of DHT. Stanozolol is metabolized in the liver, ultimately becoming glucuronide and sulfate conjugates. Its biological half-life is reported to be 9 hours when taken by mouth and 24 hours when given by intramuscular injection in the form of an aqueous suspension. It is said to have a duration of action of one week or more via intramuscular injection.
3 April The U.S. Department of Defense announced that the death toll for American soldiers in the war had exceeded the 32,629 who had died in the Korean War, based on 312 additional deaths during the week from March 22 to March 28 to bring the toll to 33,641. Laird announced that the U.S. sought to "Vietnamize" the war as quickly as possible but that troop withdrawals would not take place while the PAVN/VC was conducting attacks.
==== Closed-loop recycling ==== There are several other harmful environmental impact from synthetic textile production, including large amount of greenhouse gas emissions, high energy consumption and landfill waste. A typical textile mill consumes approximately 1.6 million liters of water to produce 8,000 kilograms of fabric. This is a worldwide problem since the textile industry contributes to about 10 percent of global greenhouse gas emissions. During 2016 alone, only 1 percent of the 180,000 tons of textile waste produced was recycled into new clothes. The remaining old textile fibers ended up in a landfill as waste. One solution that is currently being implemented within the textile industry to combat these issues is a closed loop recycling system. In the context of the textile industry, closed loop recycling involves collecting used textiles, processing them through various mechanical, chemical or biological recycling methods to turn used, worn down textiles into new textiles. Within a closed loop recycling system, textiles can either be recycled into a similar product, upcycled into a new, higher quality product, or downcycled into a new, lower quality product. This approach reduces waste, conserves resources, and minimizes the environmental impact of textile production by promoting a circular economy where materials are recycled and reused in a continuous, closed loop.
Because it has similar antiseptic qualities to chlorine, bromine can be used in the same manner as chlorine as a disinfectant or antimicrobial in applications such as swimming pools. Bromine came into this use in the United States during World War II due to a predicted shortage of chlorine. However, bromine is usually not used outside for these applications due to it being relatively more expensive than chlorine and the absence of a stabiliser to protect it from the sun. For indoor pools, it can be a good option as it is effective at a wider pH range. It is also more stable in a heated pool or hot tub.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.